Latest Stories from Healthdlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-03-21:/category/health2015-03-21T21:31:03-07:00tag:news.dlvr.it,2015-03-20:3651392015-03-20T12:11:08-07:00
- Initiative based on data that targeted delivery technology crosses
blood brain barrier -
]]>tag:news.dlvr.it,2015-03-20:3729062015-03-20T10:00:24-07:00
Improvements in the severity of preexisting nail, scalp and
palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA
responders through week 52 in ESTEEM 2
OTEZLA improved the severity of palmoplantar psoriasis at week 16 in
a subset of patients across three trials
Long-term safety profile for up to 104 weeks in ESTEEM 1 was
consistent with previously reported data from OTEZLA clinical trial
programs, with no new safety signals and no clinically meaningful
changes in laboratory values
]]>tag:news.dlvr.it,2015-03-20:3624942015-03-20T10:00:08-07:00
Detailed Results from OPT Pivotal Studies Along with Integrated
Analysis of Safety Data from Psoriasis Global Clinical Development
Program Presented at 73rd American Academy of Dermatology (AAD) Annual
Meeting
]]>tag:news.dlvr.it,2015-03-20:3675962015-03-20T09:01:16-07:00
Varieties Contain Beneficial Traits Without Foreign Genes
]]>tag:news.dlvr.it,2015-03-20:3603142015-03-20T08:33:07-07:00]]>tag:news.dlvr.it,2015-03-20:3672872015-03-20T06:29:16-07:00
Second Generation Single- and Dual-Chamber Pacemakers That Give
Patients Access to MRI Scans Now Available in the U.S.
]]>tag:news.dlvr.it,2015-03-20:3686652015-03-20T02:35:09-07:00
– Analysis Demonstrates Acceptable Safety, Statistically Significant
Reduction of Amyloid Plaque Levels and Benefit on Exploratory Clinical
Endpoints –
– Aducanumab Clinical Development Program to Advance to Phase 3 –
]]>tag:news.dlvr.it,2015-03-19:3607022015-03-19T13:59:01-07:00
TEMPO®’s automated food quality testing will help improve
food safety nationwide
]]>tag:news.dlvr.it,2015-03-19:3620832015-03-19T11:13:09-07:00
Pivotal Data to be Presented at This Year’s American Academy of
Dermatology Meeting
]]>tag:news.dlvr.it,2015-03-19:3695192015-03-19T06:30:16-07:00]]>tag:news.dlvr.it,2015-03-19:3612802015-03-19T05:00:43-07:00Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam.]]>tag:news.dlvr.it,2015-03-19:3595092015-03-19T04:30:02-07:00
All-insider round of investment funds ongoing operations and upcoming
commercial activities in Europe. Richard Dakers of the West
Health Investment Fund joins the company Board of Directors.
]]>tag:news.dlvr.it,2015-03-18:3585432015-03-18T12:57:08-07:00
CorMatrix Extends Distribution of Its Implantable Device to Buenos
Aires Based, Demedic
]]>tag:news.dlvr.it,2015-03-18:3574342015-03-18T06:45:09-07:00
Company Positioned to Expand Clinical Dermatology Programs in 2015
]]>tag:news.dlvr.it,2015-03-18:3730312015-03-18T05:00:51-07:00]]>
- Initiative based on data that targeted delivery technology crosses
blood brain barrier -
]]>
Improvements in the severity of preexisting nail, scalp and
palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA
responders through week 52 in ESTEEM 2
OTEZLA improved the severity of palmoplantar psoriasis at week 16 in
a subset of patients across three trials
Long-term safety profile for up to 104 weeks in ESTEEM 1 was
consistent with previously reported data from OTEZLA clinical trial
programs, with no new safety signals and no clinically meaningful
changes in laboratory values
]]>
Detailed Results from OPT Pivotal Studies Along with Integrated
Analysis of Safety Data from Psoriasis Global Clinical Development
Program Presented at 73rd American Academy of Dermatology (AAD) Annual
Meeting
]]>
Varieties Contain Beneficial Traits Without Foreign Genes
]]>
]]>
Second Generation Single- and Dual-Chamber Pacemakers That Give
Patients Access to MRI Scans Now Available in the U.S.
]]>
– Analysis Demonstrates Acceptable Safety, Statistically Significant
Reduction of Amyloid Plaque Levels and Benefit on Exploratory Clinical
Endpoints –
– Aducanumab Clinical Development Program to Advance to Phase 3 –
]]>
TEMPO®’s automated food quality testing will help improve
food safety nationwide
]]>
Pivotal Data to be Presented at This Year’s American Academy of
Dermatology Meeting
]]>
]]>
Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam.]]>
CorMatrix Extends Distribution of Its Implantable Device to Buenos
Aires Based, Demedic
]]>
]]>